NL1044089A - Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) - Google Patents
Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) Download PDFInfo
- Publication number
- NL1044089A NL1044089A NL1044089A NL1044089A NL1044089A NL 1044089 A NL1044089 A NL 1044089A NL 1044089 A NL1044089 A NL 1044089A NL 1044089 A NL1044089 A NL 1044089A NL 1044089 A NL1044089 A NL 1044089A
- Authority
- NL
- Netherlands
- Prior art keywords
- nmn
- resveratrol
- vitamin
- effects
- red ginseng
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Vitamin C (1) has proven antioxidant properties, while red ginseng (2) has been proven to improve immune function and healthy blood flow. In a preclinical and clinical studies, nicotine amide mononucleotide (NMN) (3) has been associated with properties such as anti-aging, cardio and brain protection, while animal studies are confirming its potential for lifespan extension. Recent studies of resveratrol (4) have shown its preventive effects for cardiovascular diseases and stroke, potential for lifespan extension and is associated with numerous health benefits. Healthy food supplement, containing a combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol should have stronger antioxidant effects and more positive effects on immune function and healthy blood flow compared to each product used separately, and is safe for use.
Description
Short Title |
Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food |
Ne » 3
(food supplement))
1044089 |
* 9 | Discussion : 5 While positive effects of Vitamin © and red ginseng have been kunen for centuries, NMN and : resverstrob gre getting fn the focus In the last years.
As this is a novel combination, below are presented effects of cach of these products individually, Vitamin € (1) Vitamin C is a patural antioxidant and crucial for endothelial and organ protection.
Vitamin U plays a role in mediating inflammation through antioxidant activities and is also Bnportant : ID as a oudhelorco-sebstrate Tor the synthesis of endogenaus adrenaline, cortisol, and vasopressin.
A growing body of evidence suggesting that vitamin C, prevents neutrophilindaced Hpid oxidation snd projects against the loss of the endothelial barier, Marked improvements in capillary fragility have alse been reported with NAM and vitamin C combinations. : Consempion of high-dose vitamin © {1250 my per day) snbancss Ametional and structural propertiss | 15 of senm lipoprotein to improve antioxidant, antbathercsclerolie, and snti-aging effects via regulation : of anti-inflammatory microRNA. : Benefits of high doses of Vanin C include attenuating oxidative stress and fiflammation, improving : vasopressor synthesis, enhancing tnnnuns cell function, improving endovascular function, and : epigenetic immonslagie modifications, : 2% Higher intakes of vitanin C and Hnoleie acid and lower intakes of fats and carbohydrates are : associated with better skin-aging appesrance.
Promoting healthy dietary behaviors may have : additional benefit for skin appeanmce fn addition to other health mgteomes in the population, : Red Ginseng {2} Korean red ginseng has been used in traditional Chinese nyedicine ax an overal! : wellness supplement Rx centuries.
It has been used to: boost the inunune system, improve heart ; 25 health, treat diabetes, incrosse energy, decrease stress, treat impotence.
Korean FDA has approved it 3 for use fir improving immune function and Tor maintaining healthy blond flow. 7 NMN (Nicotinamide Mononucleptide) Molecule (3) NMN naturally exists in avocados, : tomatoes, cucumber, cabbages, broccedl, and raw beef.
In the laboratory, it is available as : nicotinamide mononucleotide bulk powder. : 30 In the homes body, NMN is the principal source of energy withia the cells, Ax we age, cellular : energy deoreases due to the low levels of nicotinamide mononuclestide and subsequent reduction of : NAD, Administering NMN will reverse the process and compensate for the deficit. : NMN exists in both alpha io) and bets B} forms, However, B-NMN is the most active form.
This ; bioactive nucleotide is an iitermestiate in the hioxynthesis of nicotinamide adenine dinuckotide or : 35 NAD, FDA recommends that any human being needs approximately $60 mg of NMM per day. | Human Clinical Trials with NMN : ~ There are 113 cogoing clinical trials in humans that are jnwestigating NAD pracursars (NMN, : NR and Nisin], majority of them are nat completed and only few have results published. : The most important study In humans was a study in Japanese man, that showed that the ‚ 1044089
- single oral administration of NMN up to 500 mg was safe and well-tolerated in healthy men | without causing any significant deleterious effects. it has demonstrated that the oral : administration of NMN is feasible and could be a therapeutic strategy to replenish cellular NADY fevels to mitigate aging-related functional disorders In humans, \ - Trials in humans with results are: \ a An international collaborative team including researchers from Keio University in Tokyo and Washington University School of Medicine In St. Louis is running \ a Phase | human clinical study of NMN In Japan, \ Clinical trials examining the safety and efficacy of NMN are also currently being run at Washington University, investigating the effect on insulin sensitivity, : o endothelial function, lipids, body and liver fat and markers of cardiovascular \ and metabolic health. \ A randomized, double-blind, three-arm crossover pharmacokinetic study in 12 \ human subjects showed that NR raises NAD+ by as much as 2.7-fold in human \ blood with a single oral dose of 1000 mg. | o endothelial function, lipids, body and liver fat and markers of cardiovascular : and metabolic health, : A randomized, double-blind, three-arm crossover pharmacokinetic study in 12 ; human subjects showed that NR raises NAD+ by as much as 2.7-fold in human : blood with a single oral dose of 1000 mg. : o Researchers at the University of Washington have completed a clinical trial \ with 140 participants showing that orally administered NR gives a dose : dependent increase in NAD+ from 250-1000 mg/d plateauing at a 2-fold : increase in NAD+ at day nine. : Researchers have also reported positive effects of NR on vascular endothelial : Function : o in healthy middle-aged and older adults, with further investigations of motor : and cognitive changes to come. .
o Recently, reszarchers have found that a resveratrol analog called pterostilbene : combined with NR seemed to help ALS/Lou Gehrig's patients. ® : o Most recently, a placebo-controlled study assessing 500 mg of NR, taken twice ; daily by 70- to 80-year olds, showed increases in NAD+ in blood {but not : muscle.} inflammation fell and, unexpectedly, mitochondrial activity did too, : Multiple other studies are now underway assessing the effects of NR on : muscle mitochondria! function, cognition, immune function, kidney Function, 1044089 a |
: 4 | 5 o Traumatic brain injury, brown fat activity, Hpld accumulation, ensegy : metabolism, cardiovascular risk, body composition, and acetyicarnitine levels, | Clinical trials results should be available in the new few years. What we can claim with : certainly at this moment, based on clinical research data is that NMN Is safe and well : tolerated in healthy men and that it is able to successfully replenish cellular NAD+ levels, ; 10 And we know that decline in NAD levels is associated with aging.
: NMN Animal Studies : - Anima! studies are confirming that the pharmacologloal activities of NMN Include its ; role in cellular biochemiest functions, cardio protection, diabetes, Alzheimers dissase, ; and complications associated with obesity. The recent ; 15 - The recent zroundbreeking disvovery of anti-ageing activities of this chemical maisy has ; added a valuable essence In the research involving this molecuie.
! - Studies vonfirmed that pranipsdation of mitochondrial NAD levels by NRN results In ; metabolic changes that protect mitochondria against reactive oxygen species and messias: ; fragmentation, viering therapeutic approsches for pathophysiolaglo stress condition : 20 Resveratrol (4) Resveratrol is s nutrient found abundantly in the skin of red grapes that is known to : have robust antioxidant aad anti<inflavunatory properties, | The efficacy, safety, and pharmarokinetics of Resveratrol have been documented In over 244 clinical : triads, with an additional 27 clinical trials currently ongoing.
; Resveratrol has varfous biochemical and physiological effects such as anti-inflanwoatory, : 25 antioxidative, antiprodiferative and chemo-proventive effects, : Recent studies have shown its positive effects especially on cardiovascular diseases, cancer, type 2 : diabetes and neurological disorders.
i Resveratrol is reported to potentially improve the therapeutic ontcome in patients suffering from i diabetes mellitus, obesity, colorectal vancer, breast cancer, multiple myelama, metabolic syndrome, : 30 hypertension, Alzheimer's disease, stroke, cardiovascular diseases, kidney diseases, inflammatory | diseases, and rhisopharvagitis, : tt was also proven that it mimics caloric restriction, which has numerous positive effects, Resveratrol is reported to be safe at doses up to § gid, when used either alone or as a combination \ therapy,
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1043756 | 2020-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
NL1044089A true NL1044089A (en) | 2022-04-04 |
NL1044089B1 NL1044089B1 (en) | 2022-07-15 |
Family
ID=78463855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1044089A NL1044089B1 (en) | 2020-08-12 | 2021-07-06 | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) |
Country Status (1)
Country | Link |
---|---|
NL (1) | NL1044089B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108999A1 (en) * | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
WO2017062311A1 (en) * | 2015-10-07 | 2017-04-13 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
US20170266213A1 (en) * | 2015-03-16 | 2017-09-21 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products |
CN110237118A (en) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
EP3682746A1 (en) * | 2017-09-14 | 2020-07-22 | Megumi Tanaka | Anti-aging agent and anti-aging method |
-
2021
- 2021-07-06 NL NL1044089A patent/NL1044089B1/en active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108999A1 (en) * | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
US20170266213A1 (en) * | 2015-03-16 | 2017-09-21 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products |
WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
WO2017062311A1 (en) * | 2015-10-07 | 2017-04-13 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
EP3682746A1 (en) * | 2017-09-14 | 2020-07-22 | Megumi Tanaka | Anti-aging agent and anti-aging method |
CN110237118A (en) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
Also Published As
Publication number | Publication date |
---|---|
NL1044089B1 (en) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012052685A1 (en) | Product for treating cellulite, skin ageing and for preventing inflammatory processes | |
CN112739222A (en) | Anti-aging agent and anti-aging method | |
JP6209579B2 (en) | Pharmaceutical composition that is regarded as a supplementary medicine | |
JP2022010412A (en) | Anti-aging agent | |
JP2010526135A (en) | Use of slimming rare earth elements | |
NL1044089B1 (en) | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) | |
RU2657824C1 (en) | Method of biocorrection of premature aging of organism and skin | |
WO2004105749A1 (en) | Composition having autonomic nerve modulating activity and method of use thereof | |
NL1044087B1 (en) | Combination of Vitamin C, red ginseng, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement)) | |
NL1044088B1 (en) | Combination of Magnesium, Rhodiola Extract, Nicotinamide Mononucleotide (NMN) and Resveratrol as Healthy Functional Food (Dietary Supplement) | |
NL1044086B1 (en) | Combination of Zn, red ginseng, saw palmetto fruit extracts, nicotinamide mononucleotide (NMN) and resveratrol as a food supplement | |
WO2004016257A1 (en) | A composition comprising phytospingosine derivatives for apoptosis induction | |
NL1044090B1 (en) | Combination of vitamin B6, ginseng, green tea extract, Ganoderma lucidum, black cohosh root, nicotinamide mononucleotide (NMN) and resveratrol as a healthy functional food (food supplement) | |
WO2011078323A1 (en) | Active oxygen production inhibitor and anti-hypertensive agent | |
JP6573919B2 (en) | Compositions and methods for inhibiting triglyceride synthesis by synergistic combination of botanical formulations | |
TW202200129A (en) | Nicotinamide adenine dinucleotide (NAD) concentration increasing agent | |
CN109674972A (en) | The application of month peach essential oil | |
KR20170103380A (en) | Composition For Improving Skin Constitution Between Race | |
CN107890116B (en) | Leucine derivatives, compositions comprising the same and uses thereof | |
JP2008115163A (en) | Adiponectin production enhancer and stimulator | |
CN109674851A (en) | The application of Peppermint essential oil | |
WO2009110495A1 (en) | Promoter for secretion of insulin-like growth factor-1, and food or beverage containing the same | |
Du Preez | Squalene—Antioxidant of the future | |
TWI815349B (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes | |
CN108452229A (en) | Assist blood fat reducing preparation |